Darzalex Faspro
| Darzalex Faspro | |
|---|---|
| Term | Darzalex Faspro |
| Short definition | Darzalex Faspro - (pronounced) (DAR-zah-lex FAS-proh) combination of daratumumab and hyaluronidase used alone or with other medicines to treat adults with certain types of multiple myeloma or light chain amyloidosis. It is also being studied in the treatment of other types of cancer. |
| Type | Cancer terms |
| Specialty | Oncology |
| Language | English |
| Source | NCI |
| Comments | |
Darzalex Faspro - (pronounced) (DAR-zah-lex FAS-proh) combination of daratumumab and hyaluronidase used alone or with other medicines to treat adults with certain types of multiple myeloma or light chain amyloidosis. It is also being studied in the treatment of other types of cancer. Daratumumab attaches to a protein called CD38, which is found on some types of immune cells and cancer cells, including myeloma cells. Daratumumab can block CD38 and help the immune system kill cancer cells. Hyaluronidase allows daratumumab to be injected under the skin. Darzalex Faspro can be administered in less time than daratumumab alone, which is given as an infusion. Also called daratumumab and hyaluronidase
External links
- Medical encyclopedia article on Darzalex Faspro
- Wikipedia's article - Darzalex Faspro
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski